Stock Price, News, Quote and Profile of SCISPARC LTD(NASDAQ:SPRC) stock

SCISPARC LTD

NASDAQ:SPRC (12/20/2024, 8:00:02 PM)

After market: 0.219 +0.01 (+2.67%)

0.2133

0 (-0.19%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryPharmaceuticals

GICS SubIndustryPharmaceuticals

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Chartmill High Growth Momentum

EPS Q2Q%-163.64%

Sales Q2Q%N/A

CRS3.52

6 Month-76.96%

Overview

Earnings (Last)N/A N/A

Earnings (Next)N/A N/A

Ins Owners0%

Inst Owners1.33%

Market Cap2.21M

Shares10.36M

PEN/A

Fwd PEN/A

Dividend YieldN/A

AnalystsN/A

Short Float %0.93%

Short Ratio0.14

IPO12-22 2021-12-22

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

SciSparc Ltd. is a clinical stage pharmaceutical company, which focuses on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The firm is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.

Company Info

SCISPARC LTD

20 Raul Wallenberg Street, Tower A

TEL AVIV-YAFO

P: 97236103100

Employees: 3

Website: https://scisparc.com/

SPRC News

6 days ago - SciSparc LtdSciSparc Provides Updates on Status of Spin-off of its Advanced Clinical Stage Pharmaceutical Portfolio to a Publicly Traded Company

According to the LOI, SciSparc’s pharmaceuticals assets are valued at approximately US$11.6 million TEL AVIV, Israel, Dec. 16, 2024 (GLOBE NEWSWIRE) --...

3 months ago - SciSparc LtdSciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment

FDA confirms that SciSparc’s study may proceed only a month after application submission TEL AVIV, Israel, Sept. 30, 2024 (GLOBE NEWSWIRE) -- ...

3 months ago - SciSparc LtdSciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX

The intended selling valuation represents an increase of 47% from the valuation at the time of SciSparc’s initial investment in MitoCareX Bio TEL AVIV,...

SCISPARC LTD (SPRC)

Nasdaq Stock Screener

USA Stock Screener